Warburg Pincus eyes Elan unit; Boehringer inks Chinese ingredients deal;

> Private equity firm Warburg Pincus is set to enter the race to aquire Elan's drug delivery unit, according to the Sunday Times. Report

> Boehringer Ingelheim has set up a production deal with China's Hisoar, under which Boehringer will provide technical expertise and Hisoar will build new facilties to produce raw materials for drugs. Report

> Meda and Cobalt Pharmaceuticals have settled their patent dispute over Astelin, a nasal spray, with a licensing deal that allows Cobalt to launch a generic version about three months before its U.S. patent expires in November 2010. Report

> India's Wockhardt got tentative FDA approval for its version of GlaxoSmithKline's Imitrex injection drug for migraines. Report

> Soaring prices of raw materials imported from China have pushed up the sticker price of branded drugs in Indonesia by 5 percent to 10 percent. Report

> Celera tapped former FDA Chief Counsel Peter Barton Hutt to serve on its board of directors. Report

> Back in May, Bothell, WA-based Sonus Pharmaceuticals announced plans to merge with OncoGenex Technologies and operate under the name OncoGenex Pharmaceuticals. Today the new company started things off by cutting almost half of its workforce. Report

> Biotech diagnostics company Proteome Systems announced today that it will no longer pursue efforts to develop the portfolio of therapeutic compounds the company acquired through its 2005 merger with Eukarion. Report

And Finally... Fifteen percent of seniors stopped taking their meds last year when they hit the so-called "doughnut hole" gap in Medicare Part D drug coverage. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.